Wednesday, October 17, 2018
4% more people given PCSK9 inhibitor evolocumab (Repatha) died during 2.2 years (444 vs 426 deaths)
4% more people given the PCSK9 inhibitor evolocumab (Repatha) to lower cholesterol levels died during an average follow-up of 2.2 years than those given a placebo according to the FOURIER trial.
444 people (out of 13,784) given evolocumab died compared to 426 people (out of 13,780) given a placebo.
So they want me to take a drug that you have to inject that costs $14,000 per year that increases my chance of dying?
No, thank you.Read the entire article | Email this article
QUICKLINKS AND VIEW OPITONS
QUOTE OF THE DAY
Books by Larry Hobbs available on Amazon
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.